Harbin Pharmaceutical Group Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
Harbin Pharmaceutical Group has a total shareholder equity of CN¥5.9B and total debt of CN¥1.8B, which brings its debt-to-equity ratio to 30.2%. Its total assets and total liabilities are CN¥14.3B and CN¥8.3B respectively. Harbin Pharmaceutical Group's EBIT is CN¥816.0M making its interest coverage ratio 146.3. It has cash and short-term investments of CN¥3.1B.
Anahtar bilgiler
30.2%
Borç/özkaynak oranı
CN¥1.80b
Borç
| Faiz karşılama oranı | 146.3x |
| Nakit | CN¥3.13b |
| Eşitlik | CN¥5.95b |
| Toplam yükümlülükler | CN¥8.32b |
| Toplam varlıklar | CN¥14.27b |
Son finansal sağlık güncellemeleri
Recent updates
Harbin Pharmaceutical Group Co., Ltd. (SHSE:600664) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25
Investors Aren't Buying Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Earnings
Jun 25We Think Harbin Pharmaceutical Group (SHSE:600664) Can Manage Its Debt With Ease
May 25Harbin Pharmaceutical Group's (SHSE:600664) Anemic Earnings Might Be Worse Than You Think
Apr 17Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 600664's short term assets (CN¥10.7B) exceed its short term liabilities (CN¥7.9B).
Uzun Vadeli Yükümlülükler: 600664's short term assets (CN¥10.7B) exceed its long term liabilities (CN¥432.9M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 600664 has more cash than its total debt.
Borcun Azaltılması: 600664's debt to equity ratio has increased from 8.1% to 30.2% over the past 5 years.
Borç Kapsamı: 600664's debt is not well covered by operating cash flow (18%).
Faiz Kapsamı: 600664's interest payments on its debt are well covered by EBIT (146.3x coverage).